FULC - Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling June, 27 2022 02:24 PM Fulcrum Therapeutics Inc. Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now. For further details see: Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling